CardioCell: Innovative Biotechnology Company

CardioCell LLC is a global biotechnology company specializing in the development of therapeutic applications of patented ischemia-tolerant mesenchymal stem cells (itMSCs). Founded in 2013 and headquartered in San Diego, California, CardioCell focuses on creating treatments for cardiovascular diseases such as acute myocardial infarction, chronic heart failure, and peripheral artery diseases. The company's stem cells are manufactured under current Good Manufacturing Practice (GMP) conditions, ensuring the highest quality standards.

 

CardioCell's Product Range

• Therapeutic Products: Development of stem cell therapies for cardiovascular diseases, including myocardial infarction and heart failure.

• Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs): Specially designed stem cells cultured under hypoxic conditions to optimize treatment for cardiovascular conditions.

 

Why Choose CardioCell?

CardioCell leads the way in leveraging advanced stem cell technologies to treat severe cardiovascular diseases. The company aims to significantly improve patient outcomes with its innovative therapeutic approaches. With over 30 years of clinical experience underlying its research and development, CardioCell holds a strong position in the biotechnology market.

For more information, visit the official CardioCell website.